美国国家综合癌症网络预后良好中危前列腺癌男性主动监测的使用与短期结局:密歇根泌尿外科手术改进协作组初步经验
基于密歇根泌尿外科手术改进协作组2012至2020年登记数据,4,275例预后良好中危前列腺癌男性中1,321例(31%)接受主动监测,比例从2012年13%升至2020年45%。主动监测者5年免治疗概率在Gleason分级分组1为73%、分组2为57%;延迟根治性前列腺切除者不良病理比例46%高于立即手术者32%(P < .001),但短期生化复发无显著差异(log-rank检验 P = .131)。
要点
- 预后良好中危前列腺癌主动监测比例从2012年13%升至2020年45%,总体31%(1,321/4,275)。
- 主动监测者5年免治疗概率Gleason分级分组1为73%、分组2为57%。
- 延迟根治性前列腺切除者不良病理46%高于立即手术者32%(P < .001),短期生化复发无显著差异(P = .131)。
核心结论
- 预后良好中危前列腺癌男性主动监测使用显著增加。
- 超过半数主动监测者在诊断后5年仍未接受治疗。
- 多数主动监测者不会失去治愈窗口,短期肿瘤学结局与 upfront 治疗者相似。
- 作者认为主动监测对适当选择的预后良好中危前列腺癌男性是肿瘤学安全的选择。
研究设计与样本
- 回顾性分析密歇根泌尿外科手术改进协作组登记库中2012至2020年诊断的预后良好中危前列腺癌男性。
- 按诊断年份计算主动监测管理比例。
- 对选择主动监测者采用Kaplan-Meier法估计免治疗生存。
- 比较延迟根治性前列腺切除(主动监测一段时间后)与立即根治性前列腺切除者的不良病理比例和生化复发无生存。
主要发现
- 4,275例预后良好中危前列腺癌男性中1,321例(31%)接受主动监测,比例从2012年13%升至2020年45%。
- 主动监测者5年免治疗概率在Gleason分级分组1为73%、分级分组2为57%。
- 延迟根治性前列腺切除者不良病理比例46%高于立即根治性前列腺切除者32%(P < .001)。
- 两组短期生化复发无显著差异(log-rank检验 P = .131)。
临床怎么用
- 作者认为主动监测对适当选择的预后良好中危前列腺癌男性是肿瘤学安全的选择。
- 原文未据此给出具体推荐条款。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: National Comprehensive Cancer Network favorable intermediate-risk prostate cancer is a heterogeneous disease with varied oncologic and survival outcomes. We describe the Michigan Urological Surgery Improvement Collaborative's experience with the use of active surveillance and the short-term oncologic outcomes for men with favorable intermediate-risk prostate cancer.Materials and Methods:We reviewed the Michigan Urological Surgery Improvement Collaborative registry for men diagnosed with favorable intermediate-risk prostate cancer from 2012-2020. The proportion of men with favorable intermediate-risk prostate cancer managed with active surveillance was calculated by year of diagnosis. For men selecting active surveillance, the Kaplan-Meier method was used to estimate treatment-free survival. To assess for the oncologic safety of active surveillance, we compared the proportion of patients with adverse pathology and biochemical recurrence-free survival between men undergoing delayed radical prostatectomy after a period of active surveillance with men undergoing immediate radical prostatectomy. RESULTS: Of the 4,275 men with favorable intermediate-risk prostate cancer, 1,321 (31%) were managed with active surveillance, increasing from 13% in 2012 to 45% in 2020. The 5-year treatment-free probability for men with favorable intermediate-risk prostate cancer on active surveillance was 73% for Gleason Grade Group 1 and 57% for Grade Group 2 disease. More men undergoing a delayed radical prostatectomy had adverse pathology (46%) compared with immediate radical prostatectomy (32%, P < .001), yet short-term biochemical recurrence was similar between groups (log-rank test, P = .131). CONCLUSIONS: The use of active surveillance for men with favorable intermediate-risk prostate cancer has increased markedly. Over half of men with favorable intermediate-risk prostate cancer on active surveillance remained free of treatment 5 years after diagnosis. Most men on active surveillance will not lose their window of cure and have similar short-term oncologic outcomes as men undergoing up-front treatment. Active surveillance is an oncologically safe option for appropriately selected men with favorable intermediate-risk prostate cancer.
引用
- Paudel R, Madan R, Qi J, et al. The Use and Short-term Outcomes of Active Surveillance in Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer: The Initial Michigan Urological Surgery Improvement Collaborative Experience. J Urol. 2022. PMID: 36265120. doi:10.1097/JU.0000000000003012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。